Locally Advanced Solid Tumors research hub
3 indexed studies · 2 currently recruiting
- recruitingPHASE1, PHASE2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This study looks at a new drug, repotrectinib, for children and young adults (up to 25) with certain advanced cancers. It checks if the drug is safe and helps shrink tumours that have specific genetic changes called ALK, ROS1, or NTRK.
United States · Australia · Canada - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study is testing a new medicine, RO7566802, by itself and with another drug, atezolizumab, for people with advanced solid tumours. It aims to check if the treatment is safe, how it works in the body, and if it helps shrink tumours. It's an early-stage study.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
This study is looking at a new drug called repotrectinib for advanced cancers that have specific gene changes (ALK, ROS1, or NTRK). It aims to find the best dose and see how well it works in shrinking tumours and how safe it is.
United States · Australia · Belgium